The cannabis plant, known for its diverse properties, boasts a centuries-old history steeped in medicinal applications. Tracing its roots back to ancient civilizations, cannabis has been employed for its therapeutic benefits across cultures and continents.
In ancient China, cannabis was documented in medicinal texts for its potential to alleviate pain and induce relaxation. Meanwhile, in ancient India, it found a place in Ayurvedic medicine, recognized for its anti-inflammatory and pain-relieving properties. Throughout history, cannabis has been embraced in various forms, from tinctures to teas, for its potential to address a myriad of health concerns.
Fast forward to the modern era, and scientific exploration has unveiled the complex compounds within cannabis, including cannabinoids like THC and CBD. These compounds interact with the endocannabinoid system in the human body, influencing various physiological functions.
Over the past decade, the global medical cannabis market has experienced an unprecedented surge, reaching a substantial revenue milestone of 13 billion US dollars in 2023. This growth reflects not only a burgeoning acceptance of medical cannabis within the broader healthcare landscape but also a resounding demand for its therapeutic properties.
Looking forward, the medical cannabis market is poised for further expansion, with projected revenue reaching 24 billion US dollars by 2028. This substantial growth underscores the dynamic nature of the market and its increasing integration into mainstream healthcare practices. These figures highlight the evolving landscape of medical cannabis, offering both financial opportunities and advancements in global healthcare.
CBD and THC are cannabinoids, natural compounds found in the cannabis plant, each exhibiting distinct properties and effects.
While CBD and THC may seem similar, their differences are crucial. CBD lacks psychoactive effects, whereas THC often induces them. Their applications also vary: CBD is frequently used for stress-related issues and pain management, while THC comes into play for more specific medical challenges, such as appetite stimulation or sleep issues.
Tetrahydrocannabinol (THC), is the psychoactive cannabinoid responsible for the euphoric or „high“ effects of cannabis. It binds to CB1 receptors in the central nervous system and can have various effects, including pain relief, relaxation, and increased appetite. The psychoactive nature of THC makes it particularly relevant for specific medical applications, but it’s crucial to consider dosage and individual tolerance.
Cannabidiol (CBD) is a non-psychoactive cannabinoid known for its diverse potential health benefits. It doesn’t directly interact with the CB1 receptors in the brain, meaning it doesn’t induce psychoactive effects such as euphoria or a „high.“ Instead, CBD is associated with a broad range of positive effects, including anti-inflammatory properties, stress relief, and pain management.
Sie sehen gerade einen Platzhalterinhalt von Google Maps. Um auf den eigentlichen Inhalt zuzugreifen, klicken Sie auf die Schaltfläche unten. Bitte beachten Sie, dass dabei Daten an Drittanbieter weitergegeben werden.
Mehr Informationen